Breaking

OpenAI-Backed Startup Races to Design Antibody Defenses Against AI-Created Biopathogens

September 27, 2026 at 20:02 EDT

Foundation Models
Security
Healthcare

Red Queen Bio, a new biosecurity startup backed by a $15 million seed investment led by OpenAI, is using artificial intelligence to preemptively design antibody drugs targeting pathogens that frontier AI systems could theoretically create. The Boston-based company, spun out from clinical-stage mRNA firm Helix Nano, launched in November 2025 with an explicit mission to accelerate biological defenses faster than AI capabilities for pathogen design advance—a strategic approach grounded in the escalating biosecurity risks of powerful language and reasoning models.

AI Biosecurity · November 2025

Racing Ahead of Pathogenic AI

Red Queen Bio deploys AI to design antibody countermeasures against pathogens that frontier models could create.

$15M

OpenAI-led seed round

<3 mo

Antibody discovery (with AbTherx)

<1.5%

Bio AI models with safety guards

The Speed Advantage: Pre-Design vs. Response

Traditional Timeline

2–5 years

Red Queen Pre-Design

<3 months

How It Works

1. Map threats — Work with frontier AI labs to identify which pathogens advanced models could design.

2. Design countermeasures — Use AI protein algorithms + mRNA + lab automation to generate antibody candidates.

3. Pre-manufacture — Build a library of defenses before threats emerge.

4. Deploy at speed — Accelerate government biodefense response timelines.

Context: The company emerged from biosecurity concerns that AI reasoning models trained in 2024–2025 could assist in optimizing pathogenic traits. Red Queen Bio's pre-design strategy aims to stay ahead of the capability curve by compressing antibody discovery from years to months.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.